Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company, announced that President and CEO Mark Rothera will present at the virtual 2023 SVB Securities Global Biopharma Conference on February 14, 2023, at 1:00 p.m. ET. The presentation will focus on the company's advancements in treating virus-associated cancers.
A live webcast will be available on the Investors section of the Viracta website and archived for 30 days. Viracta's lead product candidate, Nana-val, is an investigational oral therapy currently evaluated in multiple clinical trials, including treatments for EBV-positive lymphoma and nasopharyngeal carcinoma.
- None.
- None.
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, is scheduled to present at the virtual 2023 SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 1:00 p.m. ET.
A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" and archived for 30 days.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other virus-related cancers.
For additional information please visit www.viracta.com.
Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
FAQ
When is the Viracta Therapeutics presentation at the SVB Securities Global Biopharma Conference?
Where can I watch the Viracta Therapeutics presentation?
What is Nana-val, the lead product candidate of Viracta?
What clinical trials is Viracta currently conducting?
What is the focus of Viracta Therapeutics?
